Clinical Trial Update: Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Gallium-68 DOTA-NeoBOMB1 and Gallium-68 PSMA-R2 PET/MRI for diagnosing recurrent prostate cancer with PSA progression; results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• Gallium-68 DOTA-NeoBOMB1 (DOTA-NeoBOMB1)
• Gallium-68 PSMA-R2 (PSMA-R2)

Snippet

Sponsor: Andrei Iagaru | Conditions: Prostate Adenocarcinoma, PSA Progression | Phase 2 | Status: COMPLETED | Results posted: 2024-01-30